Pharmaceutical company AcelRx Pharmaceuticals Inc (Nasdaq:ACRX) stated on Wednesday its net loss of USD11.6m (USD0.23 per basic and diluted share) for its first quarter 2018 financial results.
This marks a rise in earnings when compared with net loss of USD15.6m (USD0.34 per basic and diluted share) for the first quarter of 2017.
Total revenue of USD343,000 was generated in 2018, down over total revenues of USD3.109m in 2017.
R&D and G&A expenses of USD7.5m were recorded for the quarter ended 31 March 2018, a decline from R&D and G&A expenses of USD11.1m for the prior year period, primarily due to lower Zalviso-related expenses attributed to the Phase 3 clinical program completed in 2017.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development